Full Press Release Details
Inc. Announces Appointment of New Board Members
Neb., May 22, 2009 - Transgenomic, Inc. (OTC BB:
announces that it has appointed Antonius P. Schuh, Ph.D. and Michael B. McNulty
to its Board of Directors.
is the Founding Chairman and Chief Executive Officer of Sorrento Therapeutics,
Inc. (STI). STI is a seed-stage biotechnology company built on a
proprietary antibody library construction technology, the STI technology, which
applies RNA transcription rather than PCR for the amplification of variable lgG
domains to yield high fidelity mAb libraries. Prior to
STI, Dr. Schuh was the Founding Chief Executive Officer and Director of
AviaraDx, Inc. AviaraDx was a molecular diagnostics laboratory company focused
on oncology testing which was acquired by bioMerieux. Before leading AviaraDx,
Dr. Schuh was Chief Executive Officer of Arcturus Bioscience, Inc. and Sequenom,
McNulty is currently General Manager of Diagnostics at Agilent Technologies,
Inc. Agilent Technologies Inc. (NYSE: A) is the world's premier
measurement company and a technology leader in communications, electronics, life
sciences and chemical analysis. Prior to his current position he was Vice
President of Laboratory Operations and Chief Compliance Officer of Berkeley
Heartlabs, Inc. Mr. McNulty has previously served as a board member for Employee
Health Programs, Bethesda, MD; Drug Free workplace, plc, London, UK; ThauMDx
LLC, Santa Barbara, CA; and International Cancer Screening Laboratories, Inc.
Mr. McNulty previously ran SmithKline Beecham's Chicago based reference
laboratory prior to the company's transition to become Quest
this announcement, Transgenomic President and CEO, Craig Tuttle, stated, "We are
very excited to have Dr. Schuh and Mr. McNulty join the Company's
Board of Directors. Combined, they have considerable experience in molecular
diagnostics and, equally important, success in leading and running diagnostic
reference laboratories. With our continued focus on growing Transgenomic's
molecular diagnostic laboratory and pharmacogenomic services lab, plus focusing
our WAVE system and related mutation detection technology for greater diagnostic
and clinical value, their participation on our board will provide a vital
increase in laboratory experience and guidance."
is a global biotechnology company that provides unique products and services for
automated high sensitivity genetic variation and mutation analysis. Their
offerings include systems, products, discovery and laboratory testing services
to the academic and medical research, clinical laboratory and pharmaceutical
markets in the fields of Pharmacogenomics and personalized medicine. Specific
offerings include WAVE DHPLC Systems, related consumables and assay kits,
Cytogenetics automated systems, and Transgenomic Pharmacogenomics and Reference
Laboratory Services. Transgenomic Pharmacogenomics and Laboratory Services
utilize their technology and expertise to provide a menu of mutation scanning
tests for over 700 cancer-associated genes and more than 60 validated diagnostic
tests to meet the needs of pharmaceutical and biotech companies, research and
clinical laboratories, physicians and patients. For more information about the
innovative systems, products and services offered by Transgenomic, please visit:
statements in this press release constitute "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995, which
involve known and unknown risks, uncertainties and other factors that may cause
actual results to be materially different from any future results, performance
or achievements expressed or implied by such statements. Forward-looking
statements include, but are not limited to, those with respect to management's
current views and estimates of future economic circumstances, industry
conditions, company performance and financial results, including the ability of
the Company to grow its involvement in the diagnostic products and services
markets. The known risks, uncertainties and other factors affecting these
forward-looking statements are described from time to time in reports to the
Securities and Exchange Commission. Any change in such factors, risks and
uncertainties may cause the actual results, events and performance to differ
materially from those referred to in such statements. Accordingly, the company
claims the protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995 with respect
to all statements contained in this press